Table 1.
Clinical and molecular characteristics of AML patients according to IGFBP2 expression groups
| Characteristic | IGFBP2 low n = 74 | IGFBP2 high n = 25 | P |
|---|---|---|---|
| Age [years] | 0.82 | ||
| Median | 58 | 57 | |
| Range | 23–80 | 19–79 | |
| Sex [%] | 0.35 | ||
| Male | 56 | 68 | |
| Leukocyte count [× 109/L] | 0.22 | ||
| Median | 7 | 31 | |
| Range | 0.5–368 | 0.5–385 | |
| LDH >350 U/l [%] | 57 | 60 | 0.82 |
| sAML [%] | 32 | 20 | 0.31 |
| BAALC expression, high [%]† | 49 | 53 | 1.0 |
| FAB Classification [no. (%)], n=89 | 66 | 23 | 0.04 |
| M0 | 5 (8) | 0 (0) | |
| M1 | 7 (11) | 5 (22) | |
| M2 | 8 (12) | 7 (30) | |
| M4eo | 4 (6) | 2 (9) | |
| M4 | 19 (29) | 4 (17) | |
| M5 | 20 (30) | 1 (4) | |
| M6 | 3 (5) | 3 (13) | |
| M7 | 0 (0) | 1 (4) | |
| FAB M4/M5 | 39 (59) | 5 (22) | 0.008 |
| Genetic risk groups‡ [no. (%)], n=91 | 68 | 23 | 0.90 |
| Favourable | 8 (12) | 4 (17) | 0.49 |
| Intermediate-I | 29 (43) | 10 (44) | 1.0 |
| Intermediate-II | 11 (16) | 3 (13) | 1.0 |
| Adverse | 20 (29) | 6 (26) | 1.0 |
| Therapy [no. (%)] | |||
| AML 2003 SAL | 40 (54) | 14 (56) | 1.0 |
| AML SORAML SAL | 13 (18) | 5 (20) | 0.77 |
| AML 2004 OSHO #069 | 21 (28) | 6 (24) | 0.80 |
| Allogeneic SCT | 30 (41) | 10 (40) | 1.0 |
| In CR1 | 13 (43) | 1 (10) | 0.07 |
FAB: French-American-British, SCT: stem cell transplantation, CR: complete remission.
†
According to median expression level; n=62.
‡
According to ELN classification.